Context Therapeutics Inc. (CNTX) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 36 institutional investors hold a position in Context Therapeutics Inc. (NASDAQ:CNTX).

• These investors collectively held 62.6% of the company's total shares outstanding in September 2025, down from 70.0% in June 2025.
• In percentage terms, this reflects as a holdings change of 2.12% quarter on quarter, and a decrease of 14.29% year over year.
• A review of institutional activity for Context Therapeutics shows 11 of 36 filers increasing their positions, while 7 reduced their stake, and 18 remained unchanged.
• This class of investors increased its holdings in Context Therapeutics to 68.96Mn shares for the 13F-cycle ending September 2025, up by 1.43Mn shares quarter on quarter, and up 11.92Mn shares year over year.
• MPM BioImpact LLC continues to be the largest institutional holder of Context Therapeutics as of September 30, 2025, with a position of 14.71Mn shares, representing 13.35% of the company's outstanding stock.
• Among the most significant buyers of Context Therapeutics during September 2025 were Avidity Partners Management LP (1.50Mn), VANGUARD GROUP INC (134.45K), Pathstone Holdings, LLC (110.24K), CITADEL ADVISORS LLC (103.36K), MARSHALL WACE, LLP (35.75K).
• Leading sellers of Context Therapeutics stock in September 2025 included Nantahala Capital Management, LLC (273.53K), Affinity Asset Advisors, LLC (115.37K), NORTHERN TRUST CORP (47.18K), RENAISSANCE TECHNOLOGIES LLC (43.80K), GEODE CAPITAL MANAGEMENT, LLC (29.23K).
• The top 10 institutional holders of Context Therapeutics for the quarter ending September 2025 included MPM BioImpact LLC (14.71Mn), Avidity Partners Management LP (8.98Mn), Deep Track Capital, LP (7.42Mn), Nextech Invest, Ltd. (7.42Mn), Blue Owl Capital Holdings LP (7.41Mn), GREAT POINT PARTNERS LLC (4.68Mn), FRANKLIN RESOURCES INC (4.00Mn), VANGUARD GROUP INC (3.50Mn), Blackstone Inc. (2.44Mn), Alyeska Investment Group, L.P. (1.66Mn).